Comparison of 1-Year Outcomes of Triple (Aspirin plus Clopidogrel plus Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin plus Clopidogrel plus Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Cheol Hyun | - |
dc.contributor.author | Lee, Jong-Young | - |
dc.contributor.author | Park, Gyung-Min | - |
dc.contributor.author | Lee, Seung-Whan | - |
dc.contributor.author | Kim, Hyun-Sook | - |
dc.contributor.author | Choi, Young Jin | - |
dc.contributor.author | Nam, Chang-Wook | - |
dc.contributor.author | Cho, Jang Hyun | - |
dc.contributor.author | Shin, Won-Yong | - |
dc.contributor.author | Bin Seo, Jae | - |
dc.contributor.author | Choi, Si Wan | - |
dc.contributor.author | Lee, Jae-Hwan | - |
dc.contributor.author | Min, Pil-Ki | - |
dc.contributor.author | Her, Sung-Ho | - |
dc.contributor.author | Lee, Pil Hyung | - |
dc.contributor.author | Ahn, Jung -Min | - |
dc.contributor.author | Park, Duk-Woo | - |
dc.contributor.author | Kang, Soo-Jin | - |
dc.contributor.author | Kim, Young-Hak | - |
dc.contributor.author | Lee, Cheol Whan | - |
dc.contributor.author | Park, Seong-Wook | - |
dc.contributor.author | Park, Seung-Jung | - |
dc.date.accessioned | 2021-08-11T12:43:41Z | - |
dc.date.available | 2021-08-11T12:43:41Z | - |
dc.date.issued | 2018-02-15 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.issn | 1879-1913 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6210 | - |
dc.description.abstract | This study sought to evaluate the impact of triple antiplatelet therapy on clinical outcomes in patients treated with second-generation drug-eluting stents (DES) for coronary artery disease. There are limited data regarding the impact of triple antiplatelet therapy in patients who underwent implantation of second-generation DES. We planned to randomly assign 2,110 patients treated with second-generation DES to triple (aspirin, clopidogrel, and cilostazol) and dual (aspirin, clopidogrel, and placebo) antiplatelet therapy groups. The primary end point was a composite of death, myocardial infarction, ischemic stroke, or target vessel revascularization (TVR) at 1 year since randomization. The study was stopped early owing to slow enrollment. In total, 404 patients (202 patients each in the triple and dual antiplatelet therapy groups) were finally enrolled. At 1 year, the primary end point had occurred in 3.6% and 9.4% of patients in the triple and dual antiplatelet therapy groups, respectively (hazard ratio [HR] of the triple group 0.396; 95% confidence interval [CI] 0.166 to 0.949; p = 0.038). There was no significant difference between the 2 groups regarding the occurrence of a composite of all-cause death, myocardial infarction, or ischemic stroke (HR 0.583; 95% CI 0.229 to 1.481; p = 0.256). However, the rates of TVR were significantly lower in the triple antiplatelet therapy group than in the dual antiplatelet therapy group (HR 0.118; 95% CI 0.015 to 0.930; p = 0.043). In conclusion, triple antiplatelet therapy with Cilostazol after implantation of second-generation DES improved clinical outcomes, mainly by reducing TVR. (C) 2017 Published by Elsevier Inc. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Excerpta Medica, Inc. | - |
dc.title | Comparison of 1-Year Outcomes of Triple (Aspirin plus Clopidogrel plus Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin plus Clopidogrel plus Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.amjcard.2017.11.005 | - |
dc.identifier.wosid | 000425484400005 | - |
dc.identifier.bibliographicCitation | American Journal of Cardiology, v.121, no.4, pp 423 - 429 | - |
dc.citation.title | American Journal of Cardiology | - |
dc.citation.volume | 121 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 423 | - |
dc.citation.endPage | 429 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ELEVATION MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | REDUCES LATE RESTENOSIS | - |
dc.subject.keywordPlus | UNIVERSAL DEFINITION | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | Triple(Aspirin + Clopidogrel + Cilostazol) DualAntiplatelet Therapy (Aspirin + Clopidogrel + Placebo) | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.